Dietary fats

Industrial trans fats are unambiguously harmful; saturated fats are mixed (neutral in fermented dairy, problematic in fatty ruminant meat); polyunsaturated fats — both omega-3 and, contrary to a popular framing, omega-6 — are protective; monounsaturated fat, chiefly extra-virgin olive oil, anchors the most-evidenced longevity diet on the planet; and dietary cholesterol from eggs is largely safe within sensible thresholds. This article walks each fat class with the 2024–2026 evidence, including the recent epigenetic-clock work that puts tentative numbers — in years of biological age — on each fat type.

The framework, briefly

Four practical rules organise almost all of the evidence:

1. Eliminate industrial trans fats. Non-negotiable. The molecule is biologically alien and the dose-response is steep.
2. Don't reduce saturated fat in isolation — substitute it. The benefit comes from what you put in instead. Polyunsaturated and monounsaturated fats win; refined carbohydrates don't.
3. Get adequate omega-3s. From fatty fish twice a week, or from a 1 g/day supplement of the marine omega-3s EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — see Omega-3.
4. The food matrix matters. Saturated fat in fermented dairy behaves differently from saturated fat in processed meat; cholesterol in whole eggs behaves differently from cholesterol in a Western brunch.

The reason amount barely makes the list is that the trials testing it came up empty. The Women's Health Initiative (WHI) Dietary Modification Trial randomised 48,835 postmenopausal women to a low-fat pattern (target 20% of energy from fat) and over ~8 years found no reduction in coronary heart disease, stroke, or total cardiovascular disease.^[1] The large PURE cohort pointed the same way, with higher total fat intake tracking lower total mortality and very-high carbohydrate intake tracking higher mortality — though PURE is observational, much of its carbohydrate signal came from low-income subsistence populations, and it drew heavy methodological criticism.^[2] Neither overturns the substitution framework; both anchor the "type, not amount" reading.

The rest of this article is the evidence behind those four lines.

Industrial trans fats — the one molecule to actually eliminate

Industrial trans fats, formed by the partial hydrogenation of vegetable oils, are the most metabolically deleterious dietary fat ever characterised. The trans double-bond geometry produces a rigid, linear molecule that mimics a saturated fat structurally but is biologically alien — disrupting endothelial function, lipid homeostasis, and DNA methylation.

The dose-response is sharp. A 1% increase in trans-fat energy associates with roughly 6% higher all-cause mortality and 6% higher cardiovascular mortality.^[3] Trans fats uniquely degrade the lipid profile in both directions simultaneously — raising LDL ("bad") cholesterol (LDL-C) while suppressing HDL ("good") cholesterol (HDL-C) — and they accelerate the atherosclerotic cascade by upregulating ICAM-1, VCAM-1, and E-selectin on the vascular endothelium.

Newer epigenetic work has shown that trans-fat-enriched diets alter DNA methylation at the TNF (inflammatory cytokine) and ADIPOQ (adiponectin) loci within seven weeks of exposure in healthy young adults — a pre-clinical signature of cardiovascular pathology that precedes overt biomarker changes.^[4]

The good news is policy-driven. Between 1990 and 2021, the age-standardised mortality and disability burden attributable to high trans-fat intake fell by ~69% globally, driven by industrial-trans-fat bans in high-income regions.^[5] The FDA's final 2015 determination phased out partially hydrogenated oils in the US by 2018–2020; the EU's 2019/649 regulation capped industrial trans fats at 2 g per 100 g of fat from 2021. The residual exposure today is concentrated in unregulated markets and some legacy processed foods; reading ingredient labels for "partially hydrogenated oil" is still the reliable individual safeguard.

Naturally occurring (ruminant) trans fats — chiefly vaccenic acid and conjugated linoleic acid in dairy and meat — are biologically distinct from the industrial form and are not associated with cardiovascular harm at typical dietary intakes.

Saturated fat — the substitution effect dominates

Saturated fatty acids (SFAs) are where the 1980s consensus has been most heavily revised. The honest current reading: non-specific SFA reduction does little on its own; what matters is what replaces them.

The strongest RCT-grade evidence is the Cochrane review pooling 15 trials and ~56,675 participants, which found that reducing saturated fat for at least two years cut combined cardiovascular events by about 17% (RR 0.83, 95% CI 0.70–0.98; GRADE moderate-quality), with little or no effect on all-cause or coronary mortality. (Throughout, the bracketed 95% confidence interval is the range where the true effect most plausibly lies; when it stays entirely below 1.0, as here, the result is unlikely to be chance.)^[6] Crucially, meta-regression showed that greater falls in saturated fat — and the resulting greater falls in serum cholesterol — produced greater event reductions, and the benefit came specifically from replacement with polyunsaturated fat or starchy foods.

That sits in apparent tension with meta-analyses of trials reducing saturated fat without specifying a substitute, which show essentially null effects on all-cause mortality (RR ~1.01), cardiovascular mortality (RR ~0.94), and coronary events (RR ~0.85, not statistically significant).^[7] The two reconcile cleanly: unspecified-substitute SFA cutting is weak, while the SFA→PUFA replacement and the magnitude of cholesterol-lowering drive the benefit. Reduction with explicit substitution tells the sharper story:

That table is the 2017 American Heart Association (AHA) Presidential Advisory's central point, and it has held up across the subsequent decade of randomised and observational data.^[8] The unifying mechanism is ApoB-containing lipoproteins: most of saturated fat's cardiovascular effect runs through its elevation of LDL (and other ApoB particles), which is exactly why the substitution framework works and why the Cochrane cholesterol-magnitude relationship holds.

The food matrix is doing real work

Not all saturated fat is biologically equivalent. SFAs from fermented dairy (yogurt, kefir, traditionally aged cheese) carry a neutral-to-mildly-protective cardiovascular signal in cohort meta-analyses; SFAs from fatty ruminant meats track consistently with higher CVD incidence.^[9] The reasons are physical and biochemical:

• Fermented dairy delivers saturated fat embedded in a calcium-, vitamin-K2-, and bacterial-metabolite-rich matrix. The calcium-fatty-acid soap formation and the food-matrix architecture blunt LDL elevation that pure SFAs would produce. The biomarker support is a pooled analysis of 16 prospective cohorts (63,682 participants), in which higher blood levels of the dairy-fat fatty acids C15:0 and C17:0 tracked with roughly 20% and 35% lower rates of new type 2 diabetes respectively (HR 0.80 and 0.65) — though these are largely intake markers and direct causality is unproven.^[10]
• Fatty meat delivers the same molecules without the matrix advantages — and with Neu5Gc, heme iron, TMAO precursors, and (when high-heat cooked) HCAs and PAHs. See Red and processed meat.

This is why "how much saturated fat?" is less informative than "saturated fat from what?".

The epigenetic-age signal

A National Health and Nutrition Examination Survey (NHANES) epigenetic-clock analysis of 1,771 US adults aged 50+ links a doubling of total saturated-fat intake to a 0.42-year increase in GrimAge2 (95% CI 0.02–0.83), an epigenetic clock specifically trained to predict time to death.^[11] Specific fatty acids vary in effect:

• Palmitic acid (16:0): +0.55 years of GrimAge2 per doubling (0.07–1.04) — the most damaging single saturated species.
• Stearic acid (18:0): +0.43 years per doubling (0.06–0.80).

Read these as suggestive, not settled: the analysis is cross-sectional, so it shows correlation on a surrogate rather than a proven aging effect, and the hard-outcome RCT data above (Cochrane RR 0.83) carry the argument. One inconvenient finding in the same paper deserves stating: a doubling of monounsaturated fat was also associated with greater GrimAge2 (+0.54 years), which sits awkwardly beside the olive-oil evidence and is a reason not to over-read any single clock analysis.

A 2024 Mendelian randomization study using genetic instrumental variables found SFA intake causally and negatively associated with leukocyte telomere length (OR 0.80, 95% CI 0.70–0.91), confirming that the cohort signal isn't pure confounding.^[12]

The bottom line on saturated fat

A large 2025 cohort makes the substitution concrete: across 221,054 adults followed up to 33 years, the highest butter intake carried 15% higher total mortality (HR 1.15) while the highest plant-oil intake carried 16% lower (HR 0.84), and modelling a swap of ~10 g/day of butter for plant oils was associated with ~17% lower total and cancer mortality.^[13] Observational, with the usual healthy-user caveats (higher-butter consumers smoked more and moved less), and partly industry-funded — but directionally consistent with the RCT picture.

Cap saturated fat at roughly 10% of total energy (the standard public-health threshold) — but spend most of your effort thinking about what replaces it. Olive oil and nuts are the highest-evidence substitutes. Refined carbohydrates are not. Fermented dairy is largely a wash. Fatty ruminant meat in volume is the form most worth limiting.

Polyunsaturated fats — the geroprotective class

Polyunsaturated fatty acids (PUFAs) — both omega-3 and omega-6 — are essential nutrients with the strongest aging-deceleration signal among dietary fats. The 2024–2026 epigenetic-clock work has put numbers on it.

Omega-3s: the strongest single epigenetic signal

The DO-HEALTH trial, a 2,157-participant, three-year RCT in European seniors, tested 1 g/day of EPA+DHA omega-3 supplementation. In an epigenetic-clock analysis, omega-3 slowed three of four next-generation DNA-methylation clocks (PhenoAge, GrimAge2, DunedinPACE), corresponding to roughly 2.9–3.8 months of biological age reduction over three years, with the effect compounding additively alongside exercise and vitamin D3.^[14]

That clock result is real but should be read with care, because it is the smaller part of the trial's story. It was a post-hoc analysis of the healthier Swiss subset only (n=777), with two measurement timepoints and no single pre-specified primary outcome. DO-HEALTH's six pre-specified primary clinical endpoints were all null for omega-3 (blood pressure, physical function, cognition, fractures, infections), and in the trial omega-3 modestly raised LDL-C (+0.11 mmol/L) and total cholesterol while not reducing major cardiovascular events. So the honest framing is a small, positive surrogate-endpoint signal in a trial whose hard clinical endpoints were null — an early epigenetic-aging readout, not a settled geroprotective result. The clinical-outcome RCTs for marine omega-3 (VITAL, ASCEND, REDUCE-IT, STRENGTH) and the atrial-fibrillation dose signal are covered under Omega-3.

Subtype-specific NHANES analyses extend the picture: a doubling of total PUFA intake associates with roughly 0.6–0.7 years of decreased biological age across Horvath1, Hannum, and PhenoAge, and omega-3 intake tracks with lower epigenetic age on four clocks.^[15] Alpha-linolenic acid (ALA, plant-derived 18:3) carried the largest single effect size, −0.69 years on PhenoAge — though its confidence interval (−1.31 to 0.06) crossed the null, so that particular number is the weakest link in the chain, and the whole analysis is cross-sectional. For ALA specifically, a peer-reviewed dose-response meta-analysis found higher intake modestly lowered all-cause and cardiovascular mortality but slightly raised cancer mortality — a more mixed picture than the single biological-age figure implies.^[16]

The mechanism runs through eicosanoid signalling, membrane fluidity, and PPARα-driven mitochondrial biogenesis. PUFAs are also direct substrates for specialized pro-resolving mediators (SPMs) — resolvins, protectins, maresins — that actively terminate inflammation rather than merely suppressing it.

If you eat fatty fish (salmon, sardines, mackerel, herring) twice a week, you're covered. If you don't, a 1 g/day EPA+DHA supplement is one of the few supplements with a randomized epigenetic-aging signal. The full discussion of doses, freshness, oxidation, and form is under Omega-3.

The "seed oil myth" — what the evidence actually says

The hypothesis that omega-6 linoleic acid (LA), the dominant PUFA in sunflower, safflower, soybean, canola, and corn oils, drives systemic inflammation and cardiovascular disease has become a popular online position. The 2024–2026 evidence resolutely disconfirms it.

A 2025 umbrella review pooling 150 cohort meta-analyses found that higher dietary intake and higher circulating omega-6 levels associate with lower risk of cardiovascular disease, several cancers, and all-cause mortality.^[17] Higher biomarker-confirmed linoleic acid intake associates with neutral-to-favourable cardiovascular outcomes; LA does not raise circulating inflammatory biomarkers in human RCTs.^[18] The AHA, Cochrane, and most national authorities all classify PUFA substitution for SFA as cardioprotective.

The remaining valid critiques of "seed oils":

• Industrial deep-frying repeatedly heated oils (commercial fryers running for hours) produces oxidized lipid species that are measurably pro-inflammatory. The exposure issue here is real and is about cooking practice, not the molecule.
• Refined oils are calorie-dense and show up alongside refined sugar, refined flour, and additives inside ultra-processed foods — and that surrounding matrix is what drives the harm, not the LA molecule per se. See Ultra-processed food.

The fixed reading: avoid ultra-processed foods that contain seed oils alongside refined sugar, refined flour, and additives. Avoid the deep-fried-at-the-commercial-chain category. Don't avoid linoleic acid in a home kitchen using fresh oil at moderate heat.

The omega-6 : omega-3 ratio

The two PUFA families compete for the same desaturase enzymes (especially Δ6-desaturase). When omega-6 vastly outnumbers omega-3 — as in the modern Western diet, often 15:1 or 20:1 — that competition skews eicosanoid metabolism toward a pro-inflammatory baseline. The UK Biobank analysis of 183,230 adults identified the circulating omega-6:omega-3 ratio as an independent mortality predictor; adding the ratio metric to the SCORE2 cardiovascular risk model improved prediction accuracy.^[19]

A reasonable target is between 1:1 and 4:1. You don't get there by avoiding linoleic acid — you get there by adding omega-3 (fatty fish twice a week or 1 g/day EPA+DHA), reducing ultra-processed food (which is omega-6-saturated), and using olive oil rather than corn or soybean oil as the primary cooking fat.

Monounsaturated fats and extra-virgin olive oil

Monounsaturated fatty acids (MUFAs), characterised by a single double bond and dominated dietarily by oleic acid, are the lipid backbone of the Mediterranean diet — the most-evidenced longevity dietary pattern by a comfortable margin. See Dietary patterns.

The headline trial: PREDIMED, a 7,447-participant Spanish randomised trial in adults at high cardiovascular risk, showed a ~30% reduction in major cardiovascular events in the Mediterranean-plus-EVOO and Mediterranean-plus-nuts arms versus a low-fat control, sustained over five years.^[20] One caveat belongs on the record: the original 2013 paper was retracted in 2018 and republished after a statistical audit found randomisation deviations affecting ~21% of participants (1,588 of 7,447), including a clinic that misused the randomisation table and whole households co-assigned to one arm. The corrected intention-to-treat analysis still showed roughly the same benefit (EVOO arm HR 0.69, 95% CI 0.53–0.91), so the conclusion survived — but the trial was also part-funded by the Spanish olive and nut industries. An umbrella review of 31 meta-analyses confirmed that olive oil consumption associates with reduced cardiovascular disease, diabetes, and several cancers, with the strongest signal at the highest consumption quintile.^[21]

A Mendelian-randomization analysis found a causal positive association between circulating MUFA levels and preserved telomere length (OR 1.15, 95% CI 1.07–1.24).^[22] Extra-virgin olive oil also delivers a phenolic-compound payload (oleocanthal, hydroxytyrosol, oleuropein) that is anti-inflammatory and inhibits LDL oxidation independently of its fatty-acid content.

The clinically interesting nuance: in a small head-to-head RCT, 27 healthy young women took 40 g/day of either high-phenolic EVOO or sunflower oil for 8 weeks. Sunflower oil lowered LDL-C, while EVOO raised it (+5.1 mg/dL) — yet EVOO improved fasting insulin (−0.31 µU/mL) where sunflower oil did not.^[23] With 27 participants over 8 weeks and surrogate endpoints only, this is a nuance to hold lightly, not a reason to switch oils. The cardiovascular benefit of EVOO is largest when it replaces saturated fat from animal sources, less compelling when displacing other already-healthy plant oils.

Avocado oil and nut oils are reasonable higher-heat alternatives with similar profiles. Other plant oils — canola, soybean — sit in the neutral middle: balanced MUFA/PUFA profiles, no harm signal in cohort data, less phenolic benefit than EVOO.

Coconut oil is not a health food. A meta-analysis of 16 trials found that, versus non-tropical vegetable oils, coconut oil raised LDL-C by 10.5 mg/dL (and HDL-C by 4.0 mg/dL), with no effect on triglycerides, weight, glycaemia, or inflammation.^[24] The "medium-chain triglyceride" framing is misleading: coconut oil's dominant fat is lauric acid (C12), which is absorbed via chylomicrons and behaves metabolically like a long-chain saturated fat, raising LDL rather than acting like a true MCT.

Dietary cholesterol and eggs

Eggs are the most-litigated single food in modern nutrition science. The current evidence permits a fairly specific reading.

The geographic paradox

Cohort outcomes for egg consumption differ sharply by population, in a way that maps cleanly onto the rest of the dietary pattern around them:^[25]

The simplest explanation: the companion foods are doing the work. In Western diets, an egg is typically eaten with bacon, sausage, refined-flour toast, and butter — a high-sodium, high-saturated-fat, ultra-processed meal. In a traditional Japanese diet, the same egg is eaten with rice, miso, fish, and vegetables. The egg molecule is identical; the matrix is not.

The non-linear threshold

Egg consumption shows a non-linear dose-response on mortality.^[26] Low to moderate intake (up to ~50 g/day, or one egg) does not elevate mortality risk in any major cohort. Statistically significant elevation begins only above ~75 g/day (1.5+ eggs per day). The American Heart Association's current position permits up to one egg per day within an otherwise healthy dietary pattern.

Why the lipid panel doesn't fully respond

When healthy adults eat extra eggs, the liver compensates: endogenous cholesterol synthesis is down-regulated. RCT meta-analyses show that each 100 mg/day increase in dietary cholesterol raises serum total cholesterol by only ~2.2–2.5 mg/dL, and the LDL:HDL ratio — the atherogenic metric — remains essentially stable.^[27] In an intervention study, Japanese adults adding one egg per day for four weeks actually improved HDL-C and reduced oxidised LDL — the egg's intrinsic antioxidant package (lutein, zeaxanthin, choline-phospholipids) protects rather than damages lipoprotein quality.

Phosphatidylcholine and the brain

Eggs are also the densest dietary source of phosphatidylcholine — the phospholipid that makes up roughly 30% of brain tissue lipid mass by weight and serves as the precursor to acetylcholine, the neurotransmitter most damaged in Alzheimer's. Choline delivered as egg-yolk phospholipid produces a ~4× higher plasma response than equivalent doses of synthetic choline bitartrate, with parallel increases in downstream metabolites betaine and dimethylglycine.^[28] Maintaining adequate plasma phosphatidylcholine through diet appears to preserve structural cognitive resilience in late life.

The bottom line on eggs

Whole eggs at up to 5–7 per week are compatible with most longevity-oriented dietary patterns for healthy adults. Eggs delivered alongside vegetables, whole grains, and unsaturated fats behave differently from eggs delivered alongside bacon, white toast, and processed cheese — and that's where the cohort heterogeneity comes from. The phosphatidylcholine and lutein/zeaxanthin payload is a useful side benefit.

Diabetics may warrant more caution; some cohort data show a stronger CVD association with eggs in established type 2 diabetes specifically.^[29]

Practical guidance

A defensible, evidence-aligned framework for fat quality:

Eliminate industrial trans fats. Read ingredient labels for "partially hydrogenated oil" or PHO. In regulated markets (US, EU, UK, most of Europe), residual exposure is now low; in unregulated markets the exposure can still be substantial.

Anchor on extra-virgin olive oil. EVOO is the highest-evidence single dietary fat. Use it as the default cooking and dressing oil. Avocado oil and nut oils are reasonable for high-heat cooking; canola, sunflower, and safflower are neutral.

Get omega-3s. Fatty fish twice a week or 1 g/day EPA+DHA. DO-HEALTH produced a small randomized epigenetic-aging signal, though its primary clinical endpoints were null; the marine-omega-3 outcome trials and dose caveats live under Omega-3.

Don't fear linoleic acid in a home kitchen. Avoid the ultra-processed-food matrix and the commercial deep-fryer exposure, not the oil molecule.

Cap saturated fat near ~10% of energy — but spend more thought on the substitution. Replace it with PUFA or MUFA. Replacing it with refined carbohydrates produces no benefit.

Distinguish the food matrix. SFAs from fermented dairy are not equivalent to SFAs from processed or fatty meat. The matrix is doing real biological work.

Eggs: up to one per day is fine for most healthy adults. Pair them with vegetables and whole grains rather than bacon and refined-flour bread. Diabetics warrant a more conservative cap.

Aim for an omega-6:omega-3 ratio of 1:1 to 4:1. You achieve this by adding omega-3 and reducing ultra-processed food, not by hunting linoleic acid out of your kitchen.

Further reading

• Sacks FM et al. Dietary fats and cardiovascular disease — AHA Presidential Advisory. Circulation 2017.^[30]
• Marklund M et al. Biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality. Circulation 2019.^[31]
• Sadeghi R et al. Dietary and circulating omega-6 fatty acids and cardiovascular disease, cancer, and mortality — global meta-analysis of 150 cohorts. J Transl Med 2025.^[32]
• de Goede J et al. Dairy consumption and risk of stroke — systematic review and updated dose-response meta-analysis. JAHA 2016.^[33]
• Estruch R et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts — PREDIMED. NEJM 2018.^[34]
• Bischoff-Ferrari HA et al. Individual and additive effects of vitamin D, omega-3, and exercise on DNA-methylation clocks of biological aging — DO-HEALTH. 2025.^[35]
• Bozack AK et al. Dietary fatty acids and epigenetic aging in US adults: results from the National Health and Nutrition Examination Survey. npj Aging 2025.^[36]
• Morris EA et al. Cardiovascular effects of extra virgin olive oil in healthy reproductive-aged women: a randomized controlled trial. Pregnancy Hypertension 2026.^[37]
• Yamada S et al. Saturated fat restriction for cardiovascular disease prevention — meta-analysis of RCTs. JMA Journal 2025.^[38]
• Hooper L et al. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database of Systematic Reviews 2020.^[39]
• Zhang Y et al. Butter and plant-based oils intake and mortality. JAMA Internal Medicine 2025.^[40]
• Imamura F et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes. PLOS Medicine 2018.^[41]
• Neelakantan N et al. The effect of coconut oil consumption on cardiovascular risk factors. Circulation 2020.^[42]
• Howard BV et al. Low-fat dietary pattern and risk of cardiovascular disease — WHI Dietary Modification Trial. JAMA 2006.^[43]
• Dehghan M et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality — PURE. Lancet 2017.^[44]
• Naghshi S et al. Dietary intake and biomarkers of alpha linolenic acid and risk of all cause, cardiovascular, and cancer mortality. BMJ 2021.^[45]
• Kishimoto Y et al. Egg consumption and human health — comprehensive review. J Poultry Sci 2026.^[46]
• Zhao B et al. Associations of dietary cholesterol, serum cholesterol, and egg consumption with mortality — systematic review and meta-analysis. Circulation 2022.^[47]
• Chen Y et al. Relationship between fatty acid intake and aging — a Mendelian randomization study. 2024.^[48]
• GBD 2021 — trans fats and cardiovascular disease.^[49]

---